The cell therapy raw materials market size has grown exponentially in recent years. It will grow from $5.07 billion in 2025 to $6.1 billion in 2026 at a compound annual growth rate (CAGR) of 20.4%. The growth in the historic period can be attributed to early-stage development of cell therapies, reliance on animal-derived sera, limited scalability of cell culture processes, growing academic and clinical research in cell therapy, increasing investment in regenerative medicine.
The cell therapy raw materials market size is expected to see exponential growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 20.2%. The growth in the forecast period can be attributed to commercialization of cell and gene therapies, rising demand for car-t treatments, advancements in cell expansion and cryopreservation materials, increasing regulatory scrutiny on raw material quality, expansion of biopharmaceutical manufacturing capacity. Major trends in the forecast period include rising demand for high-quality and consistent cell culture media, increasing adoption of serum-free and chemically defined raw materials, growth in car-t and gene therapy manufacturing pipelines, expansion of outsourcing to specialized raw material suppliers, enhanced focus on regulatory compliance and traceability.
The growing adoption of regenerative medicine is expected to drive the growth of the cell therapy raw materials market in the coming years. Regenerative medicine is a medical field focused on restoring normal function by replacing, engineering, or regenerating human cells, tissues, or organs. The expansion of regenerative medicine is driven by the increasing burden of chronic and degenerative diseases, which is fueling demand for therapies that repair or replace damaged tissues rather than merely managing symptoms. Cell therapy raw materials support regenerative medicine by supplying essential components such as growth factors, cell culture media, enzymes, and scaffolds required to cultivate, expand, and maintain therapeutic cells used in tissue and organ repair or regeneration. For instance, in January 2025, according to the National Library of Medicine, a US-based biomedical library, 32 new gene therapies, including genetically modified cell therapies, were approved in 2024. Therefore, the growing use of regenerative medicine is driving the growth of the cell therapy raw materials market.
Major companies operating in the cell therapy raw materials market are focusing on developing innovative solutions, such as good manufacturing practice (GMP)-compliant manufacturing, to ensure product safety, consistency, and regulatory compliance throughout the cell therapy production process. GMP-compliant manufacturing refers to systems and processes that ensure products are consistently produced and controlled according to quality standards established by regulatory authorities, minimizing risks associated with pharmaceutical and biotechnological manufacturing. For example, in April 2025, Thermo Fisher Scientific Inc., a US-based life science and clinical research company, launched an advanced therapies collaboration center (ATxCC) in the United States to support the development and commercialization of cell and gene therapies. This center accelerates cell therapy development by offering end-to-end cGMP manufacturing support, advanced technologies, and expert process optimization, while fostering collaboration to address manufacturing challenges and accelerate commercialization.
In January 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, partnered with Akron Biotechnology to strengthen cell therapy manufacturing by integrating cGMP-compliant cytokines into Charles River’s Flex Platform. This partnership aims to streamline processing, improve scalability, and ensure regulatory compliance for advanced therapies. Akron Biotechnology is a US-based manufacturing company specializing in raw materials for cell and gene therapy development.
Major companies operating in the cell therapy raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Lonza Group AG, Sartorius Stedim Biotech SA, Bio-Techne Corporation, Stemcell Technologies Inc., Miltenyi Biotec GmbH, ACROBiosystems Co Ltd., CellGenix GmbH, Promocell GmbH, RoosterBio Inc., Akron Biotech LLC.
North America was the largest region in the cell therapy raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the cell therapy raw materials market by increasing costs for imported reagents, antibodies, and specialized cell culture components, affecting overall manufacturing expenses. Segments such as gene therapy and CAR-T cell therapy raw materials are most affected, particularly in regions like North America and Asia-Pacific that rely on global supply chains. These tariffs have led to pricing pressures and procurement challenges. However, they have also encouraged local production, supplier diversification, and investment in domestic raw material manufacturing capabilities.
The cell therapy raw materials market research report is one of a series of new reports that provides cell therapy raw materials market statistics, including cell therapy raw materials industry global market size, regional shares, competitors with a cell therapy raw materials market share, detailed cell therapy raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy raw materials industry. This cell therapy raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell therapy raw materials are the essential substances and components used in the development, manufacturing, and processing of cell-based therapies. These materials play a critical role in preserving the quality, uniformity, and safety of cell cultures across different stages of therapy production.
The main types of cell therapy raw materials include stem cell-based raw materials, gene therapy raw materials, and CAR-T cell therapy raw materials. Stem cell-based raw materials are specialized inputs designed to support the growth, maintenance, and differentiation of stem cells used in cell therapy research and manufacturing. The product portfolio includes media, sera, cell culture supplements, antibodies, reagents and buffers, and others, and these materials are extensively utilized by end users such as biopharmaceutical and pharmaceutical companies, contract research and manufacturing organizations, and others.
The cell therapy raw materials market consists of sales of serum and serum-free supplements, cryopreservation systems, and buffer systems. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell therapy raw materials market size is expected to see exponential growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 20.2%. The growth in the forecast period can be attributed to commercialization of cell and gene therapies, rising demand for car-t treatments, advancements in cell expansion and cryopreservation materials, increasing regulatory scrutiny on raw material quality, expansion of biopharmaceutical manufacturing capacity. Major trends in the forecast period include rising demand for high-quality and consistent cell culture media, increasing adoption of serum-free and chemically defined raw materials, growth in car-t and gene therapy manufacturing pipelines, expansion of outsourcing to specialized raw material suppliers, enhanced focus on regulatory compliance and traceability.
The growing adoption of regenerative medicine is expected to drive the growth of the cell therapy raw materials market in the coming years. Regenerative medicine is a medical field focused on restoring normal function by replacing, engineering, or regenerating human cells, tissues, or organs. The expansion of regenerative medicine is driven by the increasing burden of chronic and degenerative diseases, which is fueling demand for therapies that repair or replace damaged tissues rather than merely managing symptoms. Cell therapy raw materials support regenerative medicine by supplying essential components such as growth factors, cell culture media, enzymes, and scaffolds required to cultivate, expand, and maintain therapeutic cells used in tissue and organ repair or regeneration. For instance, in January 2025, according to the National Library of Medicine, a US-based biomedical library, 32 new gene therapies, including genetically modified cell therapies, were approved in 2024. Therefore, the growing use of regenerative medicine is driving the growth of the cell therapy raw materials market.
Major companies operating in the cell therapy raw materials market are focusing on developing innovative solutions, such as good manufacturing practice (GMP)-compliant manufacturing, to ensure product safety, consistency, and regulatory compliance throughout the cell therapy production process. GMP-compliant manufacturing refers to systems and processes that ensure products are consistently produced and controlled according to quality standards established by regulatory authorities, minimizing risks associated with pharmaceutical and biotechnological manufacturing. For example, in April 2025, Thermo Fisher Scientific Inc., a US-based life science and clinical research company, launched an advanced therapies collaboration center (ATxCC) in the United States to support the development and commercialization of cell and gene therapies. This center accelerates cell therapy development by offering end-to-end cGMP manufacturing support, advanced technologies, and expert process optimization, while fostering collaboration to address manufacturing challenges and accelerate commercialization.
In January 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, partnered with Akron Biotechnology to strengthen cell therapy manufacturing by integrating cGMP-compliant cytokines into Charles River’s Flex Platform. This partnership aims to streamline processing, improve scalability, and ensure regulatory compliance for advanced therapies. Akron Biotechnology is a US-based manufacturing company specializing in raw materials for cell and gene therapy development.
Major companies operating in the cell therapy raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Lonza Group AG, Sartorius Stedim Biotech SA, Bio-Techne Corporation, Stemcell Technologies Inc., Miltenyi Biotec GmbH, ACROBiosystems Co Ltd., CellGenix GmbH, Promocell GmbH, RoosterBio Inc., Akron Biotech LLC.
North America was the largest region in the cell therapy raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the cell therapy raw materials market by increasing costs for imported reagents, antibodies, and specialized cell culture components, affecting overall manufacturing expenses. Segments such as gene therapy and CAR-T cell therapy raw materials are most affected, particularly in regions like North America and Asia-Pacific that rely on global supply chains. These tariffs have led to pricing pressures and procurement challenges. However, they have also encouraged local production, supplier diversification, and investment in domestic raw material manufacturing capabilities.
The cell therapy raw materials market research report is one of a series of new reports that provides cell therapy raw materials market statistics, including cell therapy raw materials industry global market size, regional shares, competitors with a cell therapy raw materials market share, detailed cell therapy raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy raw materials industry. This cell therapy raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell therapy raw materials are the essential substances and components used in the development, manufacturing, and processing of cell-based therapies. These materials play a critical role in preserving the quality, uniformity, and safety of cell cultures across different stages of therapy production.
The main types of cell therapy raw materials include stem cell-based raw materials, gene therapy raw materials, and CAR-T cell therapy raw materials. Stem cell-based raw materials are specialized inputs designed to support the growth, maintenance, and differentiation of stem cells used in cell therapy research and manufacturing. The product portfolio includes media, sera, cell culture supplements, antibodies, reagents and buffers, and others, and these materials are extensively utilized by end users such as biopharmaceutical and pharmaceutical companies, contract research and manufacturing organizations, and others.
The cell therapy raw materials market consists of sales of serum and serum-free supplements, cryopreservation systems, and buffer systems. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell Therapy Raw Materials Market Characteristics
3. Cell Therapy Raw Materials Market Supply Chain Analysis
4. Global Cell Therapy Raw Materials Market Trends and Strategies
5. Cell Therapy Raw Materials Market Analysis of End Use Industries
7. Global Cell Therapy Raw Materials Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell Therapy Raw Materials Total Addressable Market (TAM) Analysis for the Market
9. Cell Therapy Raw Materials Market Segmentation
10. Cell Therapy Raw Materials Market Regional and Country Analysis
11. Asia-Pacific Cell Therapy Raw Materials Market
12. China Cell Therapy Raw Materials Market
13. India Cell Therapy Raw Materials Market
14. Japan Cell Therapy Raw Materials Market
15. Australia Cell Therapy Raw Materials Market
16. Indonesia Cell Therapy Raw Materials Market
17. South Korea Cell Therapy Raw Materials Market
18. Taiwan Cell Therapy Raw Materials Market
19. South East Asia Cell Therapy Raw Materials Market
20. Western Europe Cell Therapy Raw Materials Market
21. UK Cell Therapy Raw Materials Market
22. Germany Cell Therapy Raw Materials Market
23. France Cell Therapy Raw Materials Market
24. Italy Cell Therapy Raw Materials Market
25. Spain Cell Therapy Raw Materials Market
26. Eastern Europe Cell Therapy Raw Materials Market
27. Russia Cell Therapy Raw Materials Market
28. North America Cell Therapy Raw Materials Market
29. USA Cell Therapy Raw Materials Market
30. Canada Cell Therapy Raw Materials Market
31. South America Cell Therapy Raw Materials Market
32. Brazil Cell Therapy Raw Materials Market
33. Middle East Cell Therapy Raw Materials Market
34. Africa Cell Therapy Raw Materials Market
36. Cell Therapy Raw Materials Market Competitive Landscape and Company Profiles
37. Cell Therapy Raw Materials Market Other Major and Innovative Companies
40. Cell Therapy Raw Materials Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cell Therapy Raw Materials Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell therapy raw materials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell therapy raw materials? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell therapy raw materials market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Therapy Area: Stem Cell Based Raw Materials; Gene Therapy Raw Materials; CAR-T Cell Therapy Raw Materials2) By Product Type: Media; Sera; Cell Culture Supplements; Antibodies; Reagents And Buffers; Other Product Types
3) By End User: Biopharmaceutical And Pharmaceutical Companies; Contract Research Organization And Contract Manufacturing Organization; Other End Users
Subsegments:
1) By Stem Cell Based Raw Materials: Growth Factors; Cytokines; Cell Culture Media2) By Gene Therapy Raw Materials: Transfection Reagents; Nucleotides And Enzymes; Cell Culture Media For Gene Modification
3) By Car-T Cell Therapy Raw Materials: T Cell Activation Reagents; Cell Expansion Media; Cryopreservation Agents
Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Lonza Group AG; Sartorius Stedim Biotech SA; Bio-Techne Corporation; Stemcell Technologies Inc.; Miltenyi Biotec GmbH; ACROBiosystems Co Ltd.; CellGenix GmbH; Promocell GmbH; RoosterBio Inc.; Akron Biotech LLC.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell Therapy Raw Materials market report include:- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Merck KGaA
- Lonza Group AG
- Sartorius Stedim Biotech SA
- Bio-Techne Corporation
- Stemcell Technologies Inc.
- Miltenyi Biotec GmbH
- ACROBiosystems Co Ltd.
- CellGenix GmbH
- Promocell GmbH
- RoosterBio Inc.
- Akron Biotech LLC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.1 Billion |
| Forecasted Market Value ( USD | $ 12.75 Billion |
| Compound Annual Growth Rate | 20.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
